US/UK/Canada

Share

Pick a time period -
Tags ( Active)

ZICCUM AB Third Quarter Report, 2019

Summary of Interim Third Quarter Report 2019: Ziccum well on way to delivering promises made during listing.Summary of interim report - third quarter 2019 Ziccum is well on its way to delivering on the promises made when we first listed our stock – that during the year we would start three projects to develop stable, dry vaccines and biological drugs. So far during 2019 we have entered into two industrial collaborations, one with a global pharmaceutical company. We have also filed a patent application for a very important component in the development of new vaccines - Adenovirus. We

Ziccum enters into evaluation agreement with global pharmaceutical and vaccine company

Stockholm, October 3, 2019. Ziccum AB (publ) (‘Ziccum’) is to conduct an evaluation study with a global healthcare company engaged in researching and developing, vaccines and proteins to combat infectious diseases. The project will explore whether Ziccum’s air-drying capabilities could generate stable, dry-form vaccines for the company. 1-in-5 children worldwide currently do not receive even basic vaccines (WHO), and 1.5 million die every year from vaccine-preventable diseases.“We’re very proud to be starting this pilot project for such a prestigious and committed pharma company”, says

ZICCUM AB Half Year Report Q2 2019

Summary of Half Year Report second quarter 2019: This has been an eventful year for Ziccum.Summary of Half Year Report, second quarter 2019 2019 has been eventful for Ziccum: We have filed a patent application for an important component in the development of new vaccines, Adenovirus. This has resulted in several industrial players showing new interest in our technology. We also announced that we have entered into a Contract Research agreement with one of these companies, aimed at evaluating LaminarPace ™ in combination with their own project. In the second quarter we also got together

Ziccum AB (publ) to carry out Proof-of-Concept feasibility study for pharma formulation company

(Stockholm July 2, 2019) Ziccum AB (publ) (“Ziccum”) is carrying out an early-stage feasibility study for an innovative pharma company.The early-stage Proof of Concept study involves no financial exchange, but is to explore the compatibility of Ziccum’s air-drying capabilities with the company’s novel formulation. LaminarPace, Ziccum’s proprietary technology, air dries proteins, peptides and biologics at room temperature into stable, dry-form substances.

Report from Ziccum AB (publ) Annual General Meeting, May 20, 2019

(Stockholm, Sweden, May 20, 2019.)  Today, May 20, 2019, the Annual General Meeting was held for Ziccum AB (publ). Below is a summary of the decisions made. All decisions were made with the required majority. PLEASE NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.Dividend The Annual General Meeting resolved to establish the presented income statement and balance sheet. It was also resolved at the Annual General Meeting that no dividend would be paid for the financial year 2018.

Ziccum Q1 Report 2019 released

(Stockholm May 9, 2019)  Ziccum AB today releases its Q1 Report for 2019. The Report is now available on the company’s website.Summary of interim report - first quarter 2019: Successful development of a dry, temperature-stable formulation of Adenovirus resulted in a filed patent application and a significant milestone for Ziccum. Dialogue with potential Customers and partners continue with increased intensity, and an application has been submitted to Horizon 2020 step 2. January - March 2019 Net sales SEK 0,0 (190) Operating profit SEK -1,689 thousand (-137) Earnings per share

NOTICE OF ANNUAL GENERAL MEETING

The shareholders of Ziccum AB (publ) are hereby invited to attend the Annual General Meeting on May 20, 2019 at 14.00 at Hälsovägen 7 in Flemingsberg. Voting rights registration starts at. 13.30, and is cancelled when the meeting opens. NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.Right to participate The right to participate in the Annual General Meeting has been the one that has been recorded as a shareholder in the share register kept by Euroclear Sweden AB regarding the

Ziccum AB submits patent application for new temperature-stable, dry-powder formulation of Adenovirus, a key global vaccine ingredient

Huddinge, 10 January 2019. Ziccum AB (publ) has submitted a formal patent application on a new dry-powder, temperature-stable formulation of Adenovirus—a key ingredient in vaccines against Malaria, Ebola, meningitis and HIV, diseases which affect over 100 million people globally every year. The dry-powder formulation was carried out using Ziccum’s technology for air-drying biologic therapies.Temperature demands on vaccines are getting tougher. As part of its strategic mission to vaccinate more people worldwide without having to rely on costly, complex cold-chain refrigeration systems, the

Ziccum AB (publ) confirms first day of trading on Spotlight to be Thursday 25 October 2018

STOCKHOLM, SWEDEN – 22 October, 2018. On Thursday 25 October 2018, trading begins in Ziccum AB's shares and warrants of series TO 1 on Spotlight. The share will be traded under the designation ‘ZICC’, with ISIN code SE0011415595. Warrants of the series TO 1 will be traded under the trade designation ‘ZICC TO 1’, with ISIN code SE0011641950.Issue oversubscribed before listing The listing on Spotlight follows a share issue of units that raised 15.8 MSEK before issue costs for the company. The new issue was subscribed to approximately 52.7 MSEK including subscription commitments, which

Ziccum AB (publ) share issue oversubscribed before listing on Spotlight

STOCKHOLM, SWEDEN 9 October: On October 3, 2018, the subscription period for Ziccum's new issue of units was completed, prior to its planned listing on Spotlight. The new issue of 15.8 MSEK was subscribed to approximately 52.7 MSEK including subscription commitments, a subscription ratio of approximately 334%. Ziccum will therefore receive a total of 15.8 MSEK before issue costs of approx. 1 MSEK, while increasing the number of shareholders to approximately 1000. Settlement notes for units subscribed without preference under the new terms and conditions was issued on October 8, 2018.CEO

Ziccum CEO Göran Conradson tours Swedish investors: ‘powders, not liquids the future for biologic therapies’

“Biologics are one of the fastest-growing therapies in the world, yet 80% are still formulated as liquids—so they’re extremely costly to transport. We have a solution”, Ziccum CEO Göran Conradson is presenting to investors in Stockholm, Gothenburg and Malmö on the Ziccum investment case: formulating vaccines and biologics from liquids to powders.Göran Conradson, CEO for Ziccum AB, is a man on a mission: To formulate biologic therapies, including vaccines, proteins and antibodies, as powders not liquids. Making them more resilient and cost-effective to transport, and enabling Ziccum’s

Ziccum AB (publ) announces first day of subscription in new share issue, ahead of planned listing on Spotlight

STOCKHOLM, SWEDEN – 19 September, 2018. Ziccum AB (publ) has already been approved for listing on Stockholm stock market Spotlight, provided the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue begins today and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.The Investment Memorandum, Teaser and Application Form for the issue is available on the companies’ respective websites, www.ziccum.com, www.aqurat.se and www.

Ziccum AB (publ) approved for listing on Spotlight

STOCKHOLM, SWEDEN – 14 September, 2018. Ziccum AB (publ) has been approved for listing on Stockholm stock market Spotlight, provided the minimum limit of the company's new issue and the marketplace's proprietary spread requirements are met. The subscription period for the company's new share issue will begin on September 19 and continue until October 3, 2018. The first day of trading on Spotlight is scheduled for October 25, 2018.The Investment Memorandum, Teaser and Application Form for the issue will be available on the companies’ respective websites, www.ziccum.com and www.

There are no items matching the current filter
There are no more items matching the current filter
Back to top